AEON Biopharma, Inc.

AEON Healthcare Biotechnology

In the quarter to June 2026, EPS grew 96.7%, free cash flow fell 76.9% and total debt fell 88.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.23 0.01 −4.17%
Market cap
$12.1M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

0.90 0.49 0.99 0.54
Net Debt/EBITDA
(4.50) (5.75) 0.79 0.58
Debt/Assets
195.23% 622.30% 17.87% 0.00%
Debt/Equity
(0.86) (0.63) (0.09) 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.57 0.13 0.22 3.20
Capex/Depreciation
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% — 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(0.22) (0.47) (0.06) (0.07)
Cash per Share
0.51 0.30 0.15 0.07
Shareholders Equity per Share
(1.71) (5.55) (0.41) (0.30)
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
(1.71) (5.55) (0.41) (0.30)
Free Cash Flow
(2.60) (4.71) (2.64) (3.70)
Working Capital
(0.82) (3.50) (0.04) (3.35)
Capital Expenditures
0.00 0.00 — —
Net Current Asset Value
(21.19) (57.19) (18.76) (17.28)
Other line items
Quick Ratio
0.72 0.44 0.94 0.47
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.22) (0.47) (0.06) (0.07)
Capex per Share
0.00 0.00 0.00 0.00
Average Payables
3.58 3.43 1.96 3.30
Average Assets
6.37 4.35 11.21 8.79
Average Common Equity
(25.98) (41.80) (14.04) (15.61)
Capex to Sales
0.00 0.00 — —

Fold the line items

Columns are period end dates